Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 18/20 | 0.43 |
| ▸ | KDR | P35968 | 9/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 11/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 11/20 | 0.39 |
| ▸ | CDK2 | P24941 | 11/20 | 0.39 |
| ▸ | CDK9 | P50750 | 11/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.39 |
| ▸ | CDK7 | P50613 | 9/20 | 0.39 |
| ▸ | CCNH | P51946 | 9/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7514872 | 0.92 | CDK1 (0.49) | CDK1KDRCCNT1CCNA2CDK2 | |
| SCHEMBL6034729 | 0.87 | CDK1 (0.48) | CDK1KDRCCNT1CCNA2CDK2 | |
| SCHEMBL6034221 | 0.87 | KDR (0.51) | CDK1KDRCCNT1CCNA2CDK2 | |
| SCHEMBL6034790 | 0.83 | CDK1 (0.49) | CDK1KDRCCNT1CCNA2CDK2 | |
| SCHEMBL6033832 | 0.82 | CDK1 (0.67) | CDK1KDRCCNT1CCNA2CDK2 | |
| SCHEMBL6034477 | 0.82 | CDK1 (0.46) | CDK1KDRCCNT1CCNA2CDK2 | |
| SCHEMBL6033556 | 0.81 | KDR (0.54) | CDK1KDR | |
| SCHEMBL6034784 | 0.79 | CDK1 (0.48) | CDK1KDRCCNT1CCNA2CDK2 | |
| SCHEMBL6034239 | 0.79 | CDK1 (0.52) | CDK1KDRCCNT1CCNA2CDK2 | |
| SCHEMBL6033885 | 0.79 | KDR (0.43) | CDK1KDRCCNT1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1187816-B1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LTD (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-20040180914-A1 | 5-Cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMTIED | 2004-09-16 | — | — | US | disclosed |
| US-6579983-B1 | Potent and selective inhibitors of receptor tyrosine kinases involved in angiogenesis, especially KDR kinase and/or FGFr kinase | CELLTECH R&D LIMITED (GB) | 2003-06-17 | — | — | US | disclosed |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2002-10-10 | — | — | US | disclosed |
| EP-1187816-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | Celltech R&D Limited (GB) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000078731-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LIMITED (GB) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180914-A1 | 5-Cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | CDK1 58/4885KDR 3/4885CCNT1 215/4885 |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | CDK1 59/4885KDR 3/4885CCNT1 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.